Показано 0 из 0
Дата |
---|
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.11
|
1.14
|
1.15
|
1.1097
|
1.15
|
1.12
|
|
|
189 756.37
|
622.00
|
1.10
|
1.14
|
1.15
|
1.10
|
1.17
|
1.12
|
|
|
270 903.06
|
1 034.00
|
1.10
|
1.15
|
1.16
|
1.11
|
1.16
|
1.135
|
|
|
312 664.56
|
846.00
|
1.06
|
1.10
|
1.25
|
1.085
|
1.2525
|
1.12
|
|
|
609 310.45
|
1 460.00
|
1.23
|
1.24
|
1.02
|
1.01
|
1.289
|
1.22
|
|
|
2 365 339.80
|
3 817.00
|
0.96
|
1.06
|
0.97
|
0.95
|
1.03
|
1.03
|
|
|
230 982.12
|
659.00
|
0.97
|
1.06
|
1.04
|
0.9333
|
1.05
|
0.97
|
|
|
488 517.70
|
855.00
|
1.04
|
1.20
|
1.07
|
1.03
|
1.0899
|
1.04
|
|
|
191 608.02
|
523.00
|
1.05
|
1.07
|
1.17
|
1.07
|
1.1899
|
1.07
|
|
|
273 351.82
|
628.00
|
1.10
|
1.20
|
1.09
|
1.05
|
1.1999
|
1.15
|
|
|
523 384.18
|
1 369.00
|
Unicycive Therapeutics Inc is a biotechnology company dedicated towards developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.